Sign up USA
Proactive Investors - Run By Investors For Investors

Dual Therapeutics reports Bristol-Myers Squibb tie-up

Oncology start-up Dual Therapeutics has tied up with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds to treat cancer and other diseases.
Dual Therapeutics reports Bristol-Myers Squibb tie-up
Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialise therapeutics discovered by Dual..

Oncology start-up Dual Therapeutics  has tied up with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds to treat cancer and other diseases.

Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialise therapeutics discovered by Dual.

"We are pleased to collaborate with Bristol-Myers Squibb, a global leader in developing oncology products,"  Baiju R. Shah, chief executive of BioMotiv, the lead investor in Dual Therapeutics.

Dual Therapeutics is based on the work of investigators at Icahn School of Medicine at Mount Sinai and Case Western Reserve University

Bristol-Myers Squibb will pay an undisclosed upfront fee and development costs and Dual Therapeutics will be eligible to receive development and regulatory milestones that could total more than US$255 million for a successful compound approved in multiple indications in addition to royalties on future sales of products discovered in the collaboration.

Giles_55af4ddca6481.jpg


Register here to be notified of future BMY Company articles
View full BMY profile

Bristol Myers Squibb Timeline

Related Articles

Harley Street London street sign
Fri
The cancer treatment specialist has received funding to bring its breakthrough therapy to London.
Benjamin Franklin wearing a medical mask
March 24 2016
Constellation has identified a significant market opportunity in healthcare billing management.
AZN2.jpg
March 31 2016
Amryt Pharmaceuticals will join the London market in a deal that values it at £29.6mln. A share placing, meanwhile, will bring in £10mln to be used to develop the company’s lead treatment for a rare skin disorder.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC